Manufacturer
PFIZER IRELAND PHARMACEUTICALS
Contents
Etanercept
Indication
Signs & symptoms & inhibiting the progression of structural damage in moderately to severely active rheumatic arthritis (RA) as monotherapy or in combination w/ methotrexate (MTX) in patients w/ inadequate response to MTX alone. Active polyarticular juvenile idiopathic arthritis in childn & adolescent from 2 yr w/ inadequate response to or who have proved intolerant of MTX. Reduction of signs & symptoms of active psoriatic arthritis as monotherapy or in combination w/ MTX in patients w/ inadequate response to MTX alone. Active ankylosing spondylitis in adult. Active non-radiographic axial spondyloarthritis w/ objective signs of inflammation as indicated by elevated C-reactive protein &/or MRI evidence, who have had inadequate response to NSAID. Active disease defined as Bath Ankylosing Spondylitis Disease Activity Index score of ≥4. Moderate to severe plaque psoriasis in adult who failed to respond to, who have a contraindication to or are intolerant to other systemic therapy including cyclosporine, MTX or PUVA. Chronic severe plaque psoriasis in childn & adolescent from 6 yr who are inadequately controlled by,or are intolerant to other systemic therapies or phototherapies.
Instruction
Administer Enbrel as subcutaneous injections in the thigh, abdomen, or upper arm. Give each new injection at least 3 cm from a previous site. Do NOT inject into areas where the skin is tender, bruised, red, or hard.
Drug interaction
Higher rate of serious infections & neutropenia w/ anakinra. Increased serious adverse event incidence w/ abatacept. Decreased WBC counts w/ sulfasalazine.
Malaysia
